• Explore /
  • Poster
  • / Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).

Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).

Abstract Poster

Authors

Thomas Witzig

Thomas E. Witzig

Mayo Clinic, Rochester, MN

Thomas E. Witzig , Kami J. Maddocks , Sven De Vos , Roger M. Lyons , William Jeffery Edenfield , Jeff Porter Sharman , Julie Vose , Habte Aragaw Yimer , Helen Wei , Edward M Chan , Priti Patel , Christopher Di Simone , Mitul Gandhi , Jennifer Vaughn , Kathryn Kolibaba , Bruce D. Cheson , Felipe Samaniego

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT02362035

Citation

J Clin Oncol 37, 2019 (suppl; abstr 7519)

DOI

10.1200/JCO.2019.37.15_suppl.7519

Abstract #

7519

Poster Bd #

273

Abstract Disclosures

Similar Posters

First Author: Erel Joffe

First Author: Wojciech Jurczak

First Author: Martin Gutierrez

First Author: Martin JS Dyer